Ainos (AIMD) Competitors $2.58 -0.02 (-0.77%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock AIMD vs. ATNM, PRLD, GRCE, LIAN, NBRV, XCUR, OSTX, RANI, SCLX, and MURAShould you be buying Ainos stock or one of its competitors? The main competitors of Ainos include Actinium Pharmaceuticals (ATNM), Prelude Therapeutics (PRLD), Grace Therapeutics (GRCE), LianBio (LIAN), Nabriva Therapeutics (NBRV), Exicure (XCUR), OS Therapies (OSTX), Rani Therapeutics (RANI), Scilex (SCLX), and Mural Oncology (MURA). These companies are all part of the "pharmaceutical products" industry. Ainos vs. Its Competitors Actinium Pharmaceuticals Prelude Therapeutics Grace Therapeutics LianBio Nabriva Therapeutics Exicure OS Therapies Rani Therapeutics Scilex Mural Oncology Actinium Pharmaceuticals (NYSE:ATNM) and Ainos (NASDAQ:AIMD) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, profitability, earnings, institutional ownership, valuation, media sentiment and dividends. Do institutionals and insiders hold more shares of ATNM or AIMD? 27.5% of Actinium Pharmaceuticals shares are owned by institutional investors. 6.0% of Actinium Pharmaceuticals shares are owned by company insiders. Comparatively, 10.4% of Ainos shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has more risk & volatility, ATNM or AIMD? Actinium Pharmaceuticals has a beta of -0.32, meaning that its stock price is 132% less volatile than the S&P 500. Comparatively, Ainos has a beta of 2.13, meaning that its stock price is 113% more volatile than the S&P 500. Which has better earnings & valuation, ATNM or AIMD? Ainos has higher revenue and earnings than Actinium Pharmaceuticals. Actinium Pharmaceuticals is trading at a lower price-to-earnings ratio than Ainos, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioActinium PharmaceuticalsN/AN/A-$48.82M-$1.47-1.22Ainos$20K540.51-$14.86M-$6.45-0.40 Do analysts rate ATNM or AIMD? Actinium Pharmaceuticals currently has a consensus target price of $4.00, suggesting a potential upside of 123.46%. Given Actinium Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Actinium Pharmaceuticals is more favorable than Ainos.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Actinium Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75Ainos 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is ATNM or AIMD more profitable? Ainos' return on equity of -88.07% beat Actinium Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Actinium PharmaceuticalsN/A -100.85% -47.89% Ainos N/A -88.07%-48.60% Does the media prefer ATNM or AIMD? In the previous week, Actinium Pharmaceuticals and Actinium Pharmaceuticals both had 1 articles in the media. Actinium Pharmaceuticals' average media sentiment score of 1.11 beat Ainos' score of 0.63 indicating that Actinium Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Actinium Pharmaceuticals Positive Ainos Positive SummaryActinium Pharmaceuticals beats Ainos on 7 of the 13 factors compared between the two stocks. Get Ainos News Delivered to You Automatically Sign up to receive the latest news and ratings for AIMD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AIMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AIMD vs. The Competition Export to ExcelMetricAinosMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.90M$2.50B$5.70B$9.51BDividend YieldN/A1.75%4.69%4.01%P/E Ratio-0.409.0528.0720.05Price / Sales540.51757.64448.5799.42Price / CashN/A165.2136.2258.56Price / Book0.475.168.665.87Net Income-$14.86M$30.99M$3.25B$258.55M7 Day Performance-6.86%7.74%4.20%2.23%1 Month Performance1.67%16.18%10.82%12.76%1 Year Performance-24.63%-1.03%34.70%19.36% Ainos Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AIMDAinos1.5558 of 5 stars$2.58-0.8%N/A-24.0%$10.90M$20K-0.4040ATNMActinium Pharmaceuticals2.4567 of 5 stars$1.52-3.5%$4.00+164.0%N/A$47.26MN/A-1.0930Positive NewsPRLDPrelude Therapeutics3.6967 of 5 stars$0.81-0.5%$4.50+452.2%-84.4%$46.24M$7M-0.48120Positive NewsGRCEGrace Therapeutics2.5508 of 5 stars$3.19-3.6%$12.00+276.2%N/A$45.77MN/A-3.58N/APositive NewsLIANLianBioN/A$0.42-0.9%N/A-82.6%$45.68MN/A-0.52110NBRVNabriva TherapeuticsN/AN/AN/AN/A$45.46M$35.59M0.0070XCURExicure1.3417 of 5 stars$6.85-2.6%N/A+1,945.6%$44.41M$500K-1.7950Gap UpOSTXOS Therapies2.0616 of 5 stars$1.58+1.3%$18.00+1,039.2%N/A$44.40MN/A-1.84N/AGap UpRANIRani Therapeutics2.3416 of 5 stars$0.43-38.4%$7.33+1,605.4%-82.4%$44.14M$1.03M-0.43110Gap UpHigh Trading VolumeSCLXScilex2.3905 of 5 stars$6.73+6.5%$455.00+6,660.8%-82.1%$43.93M$56.59M-0.2380News CoverageMURAMural Oncology3.4217 of 5 stars$2.49-2.0%$12.00+381.9%-28.3%$43.86MN/A-0.32119 Related Companies and Tools Related Companies ATNM Competitors PRLD Competitors GRCE Competitors LIAN Competitors NBRV Competitors XCUR Competitors OSTX Competitors RANI Competitors SCLX Competitors MURA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AIMD) was last updated on 7/25/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ainos, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ainos With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AIMD Stock Alerts